NeuroMetrix (NASDAQ:NURO) Issues Earnings Results

NeuroMetrix (NASDAQ:NURO) announced its earnings results on Tuesday. The medical device company reported ($0.75) earnings per share (EPS) for the quarter, RTT News reports. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The business had revenue of $0.59 million during the quarter. During the same quarter last year, the firm posted ($1.66) earnings per share.

NeuroMetrix Price Performance

Shares of NURO traded up $0.06 during midday trading on Thursday, reaching $3.61. The stock had a trading volume of 11,089 shares, compared to its average volume of 26,237. The firm’s 50 day moving average price is $4.03 and its 200-day moving average price is $3.88. The company has a market capitalization of $7.33 million, a P/E ratio of -0.65 and a beta of 2.29. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of NeuroMetrix in a report on Monday. They issued a “sell” rating on the stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.